NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, ...
February 09 2021 - 8:00AM
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company
focused on discovering and developing transformative therapeutics
for patients, today announced that additional data from its Phase 1
study of NGM621, an anti-complement C3 antibody, will be featured
in an oral presentation at the Angiogenesis, Exudation, and
Degeneration 2021 – Virtual Edition.
Details of the presentation are as follows:
Abstract Title: Inhibition of Complement C3 in
Geographic Atrophy with NGM621: Phase 1 Study
ResultsPresenter Author: Charles C. Wykoff, M.D.,
Ph.D., Director of Research at Retina Consultants Houston and the
Greater Houston Retina Research FoundationDate and
Time: Feb. 12, 2021 at 11:15 AM ET
The presentation will be available on the NGM Bio website
athttps://www.ngmbio.com/rd/presentations-and-publications/.
About NGM621 and Complement C3 Inhibition
NGM621 is a humanized IgG1 monoclonal antibody engineered to
potently inhibit complement C3, with the potential for extended
every eight-week dosing without pegylation. In preclinical models,
NGM621’s high affinity binding to C3 has demonstrated the potential
for potent C3 inhibition. Preclinical data also suggest that NGM621
may not exacerbate choroidal neovascularization (CNV); the human
translation of this observation is being investigated in the
ongoing CATALINA Phase 2 clinical trial. C3 is a key component of
the complement system, which helps orchestrate the body’s response
to infection and maintains tissue homeostasis. The complement
cascade can be activated through its three distinct pathways –
classical, lectin and alternative – all of which converge to
activate C3. When this cascade is dysregulated, the immune response
may lead to the development and progression of GA. Inhibition of C3
represents a promising therapeutic approach that broadly inhibits
downstream effector functions triggered by the excessive activation
of C3, including inflammation, activation of the adaptive immune
system, opsonization (the marking of a pathogen to be destroyed by
phagocytes, a type of immune cell), phagocytosis and cell lysis
(cell death).
NGM621 was discovered by NGM under its strategic collaboration
with Merck.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and
developing novel therapeutics based on scientific understanding of
key biological pathways underlying liver and metabolic diseases,
retinal diseases and cancer. We leverage our biology-centric drug
discovery approach to uncover novel mechanisms of action and
generate proprietary insights that enable us to move rapidly into
proof-of-concept studies and deliver potential first-in-class
medicines to patients. At NGM, we aspire to operate one of the most
productive research and development engines in the
biopharmaceutical industry, with multiple programs in clinical
development. Visit us at www.ngmbio.com for more information.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as “suggest,” “aspire,” “potential,”
“engineered to” and similar expressions (as well as other words or
expressions referencing future events, conditions or circumstances)
are intended to identify forward-looking statements. These
statements include those related to: the therapeutic potential and
potential extended dosing of NGM621; NGM’s ability to advance
potentially transformative or first-in-class medicines for patients
and other statements that are not historical fact. Because such
statements deal with future events and are based on NGM’s current
expectations, they are subject to various risks and uncertainties,
and actual results, performance or achievements of NGM could differ
materially from those described in or implied by the statements in
this press release. These forward-looking statements are subject to
risks and uncertainties, including, without limitation, the risk
that NGM’s ongoing or future clinical studies in humans may show
that NGM621 is not a tolerable and effective treatment for GA or
that extended dosing with NGM621 is not possible and other risks
and uncertainties affecting NGM and its development programs, as
well as those discussed in the sections titled “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” in NGM’s quarterly report on Form 10-Q for
the quarter ended September 30, 2020, the section titled “Risk
Factors” in exhibit 99.1 to our current report on Form 8-K filed
with the United States Securities and Exchange Commission (SEC) on
January 6, 2021 and future filings and reports that NGM makes
from time to time with the SEC. Except as required by law, NGM
assumes no obligation to update these forward-looking statements or
to update the reasons if actual results differ materially from
those anticipated in the forward-looking statements.
Investor
Contact:Alex Schwartzir@ngmbio.com |
Media
Contact:Liz Melonemedia@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Apr 2023 to Apr 2024